Holen Sie sich die Stockscreener-App
26.00
3.34%
0.84
Handel nachbörslich:
26.00
Schlusskurs vom Vortag:
$25.16
Offen:
$25.27
24-Stunden-Volumen:
1.49M
Relative Volume:
1.80
Marktkapitalisierung:
$2.25B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-11.87
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
+3.34%
1M Leistung:
-2.48%
6M Leistung:
-21.90%
1J Leistung:
-23.98%
1-Tages-Spanne:
$25.27
$26.11
1-Wochen-Bereich:
$24.20
$26.23
52-Wochen-Spanne:
$24.20
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
26.00 | 2.25B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
IDEAYA Biosciences in-licenses Hengrui’s SHR-4849 - The Pharma Letter
Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld Online
IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma - Defense World
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - Kilgore News Herald
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month LowHere's Why - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.38 - Investing.com
BTIG maintains buy on Ideaya stock, target at $62 By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN
IDEAYA Secures Global Rights to Promising Cancer Drug SHR-4849 with 73% Response Rate in SCLC Trial - StockTitan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - cnhinews.com
Jane Street Group LLC Trims Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Purchases 118,438 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Wellington Management Group LLP Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online
Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Ideaya nominates KAT6/7 inhibitor as development candidate - BioWorld Online
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve
IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa
IDEAYA Announces Development Candidate Nomination of IDE251, a P - GuruFocus.com
IDEAYA nominates IDE251 for cancer treatment development - Investing.com
IDEAYA's Novel Cancer Drug Shows Promise for Breast & Lung Cancer Treatment - StockTitan
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance
Indo-Asian News Service - IANS India Pvt Ltd
State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat
(IDYA) Proactive Strategies - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online
Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK
IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com
BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ideaya Biosciences Inc-Aktie (IDYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Throne Jason | Chief Legal Officer |
Jun 27 '24 |
Option Exercise |
7.77 |
53,484 |
415,587 |
63,484 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Option Exercise |
12.86 |
28,500 |
366,510 |
28,500 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Sale |
36.24 |
28,500 |
1,032,884 |
0 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Option Exercise |
4.31 |
83,856 |
361,419 |
761,743 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Option Exercise |
4.31 |
56,711 |
244,424 |
734,598 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Option Exercise |
4.31 |
34,433 |
148,406 |
712,320 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Sale |
42.90 |
83,856 |
3,597,756 |
677,887 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Sale |
41.61 |
56,711 |
2,359,780 |
677,887 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Sale |
41.81 |
34,433 |
1,439,754 |
677,887 |
| Ruiz Briseno Andres | See Remarks |
Feb 09 '24 |
Sale |
46.02 |
2,000 |
92,045 |
24,531 |
0.60%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):